Propanc Biopharma announces new preclinical data supporting PRP's potential to treat chemotherapy resistance in pancreatic cancer

Propanc Biopharma announced new preclinical data supporting the potential of PRP to treat chemotherapy resistance in pancreatic cancer. PRP monotherapy reduced cancer cell proliferation by approximately 50-54% and suppressed long-term clonogenic survival by up to 59%.

Detected & updated continuously · Source: Nebula